AGRX - Is Agile Therapeutics Stock a Buy After Its Big FDA Win?
You've heard the old saying, "If at first you don't succeed, try, try again." Agile Therapeutics (NASDAQ: AGRX) just proved the wisdom of the adage.
In December 2017, Agile received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its contraceptive patch Twirla. The FDA rejected the biotech's regulatory submission because of concerns about quality adhesion test methods used in manufacturing the patches.
But Agile worked with the agency to address the issues. Those efforts paid off last week, with the FDA giving the biotech a nice Valentine's Day present by approving Twirla. Is Agile Therapeutics stock now a buy after its big FDA win?